Updates in Hemoglobinopathies

by Al-Tonbary, Youssef, Tricta, Fernando, El-Beshlawy, Amal, Badr, Mohamed Ahmed, Mansour, Ahmed
Published 2013

Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study

by Taher, Ali, El-Beshlawy, Amal, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Habr, Dany, Kriemler-Krahn, Ulrike, Hmissi, Abdel, Al Jefri, Abdullah
Published 2009

Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study

by Taher, Ali, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, Roubert, Bernard, El-Beshlawy, Amal
Published 2011

Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

by Taher, Ali, Elalfy, Mohsen S, Al Zir, Kusai, Daar, Shahina, Al Jefri, Abdullah, Habr, Dany, Kriemler-Krahn, Ulrike, El-Ali, Ali, Roubert, Bernard, El-Beshlawy, Amal
Published 2011

Multicenter Validation of Spin-Density Projection-Assisted R2-MRI for the Noninvasive Measurement of Liver Iron Concentration

by St Pierre, Tim G, El-Beshlawy, Amal, Elalfy, Mohsen, Al Jefri, Abdullah, Al Zir, Kusai, Daar, Shahina, Habr, Dany, Kriemler-Krahn, Ulrike, Taher, Ali
Published 2014

Worldwide survey of T2* cardiovascular magnetic resonance in Thalassaemia

by Carpenter, John-Paul, He, Taigang, Kirk, Paul, Anderson, Lisa, Porter, John B, Walker, Malcolm, Galanello, Renzo, Danjou, Fabrice, Forni, Gianluca, Kattamis, Antonis, Ladis, Vassilis, Drossou, Marouso, Vini, Demetra, Michos, Andreas, Perifanis, Vassilios, Hazirolan, Tuncay, Almeida, Ana, Aydinok, Yesim, Rangelova, Mirella, El-Beshlawy, Amal, Elalfy, Mohsen, Alnasser, Ibrahim, Daar, Shahina, Fernandes, Juliano de Lara, Pennell, Dudley J
Published 2011